Cell Therapy News/Articles, page-4585

In preclinical models, MSC are effective in ameliorating acute lung injury due to their ability to secrete paracrine factors that regulate lung endothelial and epithelial permeability, including growth factors, anti-inflammatory cytokines, and antimicrobial peptides. Based on the promising pre-clinical preliminary data and intriguing results in patients with COVID-19 associated pneumonia and ARDS as well as an established safety profile of MSC generally and in ARDS in particular, the researchers propose multiple dosing of MSCs as a study treatment to ameliorate the severity and duration of SARS-CoV-2 associated pneumonia and ARDS potentially improve survival.Intriguing results?

new study by university of Minnesota with Msc’s against Ards. They refer to prior intriguing results. Does someone have those results? Apologies if already discussed, so many threads running to keep up with information flow.

Thx Reg